Obseva (NASDAQ:OBSV) posted its quarterly earnings results on Thursday. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.19, Fidelity Earnings reports.
OBSV traded up $0.19 during midday trading on Friday, hitting $3.00. The company’s stock had a trading volume of 1,136,800 shares, compared to its average volume of 58,388. The firm has a 50-day moving average price of $7.74 and a two-hundred day moving average price of $10.14. Obseva has a 52-week low of $2.75 and a 52-week high of $16.49. The firm has a market cap of $356.09 million, a P/E ratio of -1.57 and a beta of 0.82. The company has a current ratio of 3.67, a quick ratio of 3.67 and a debt-to-equity ratio of 0.02.
OBSV has been the subject of several recent analyst reports. Wedbush restated a “buy” rating and issued a $38.00 price target on shares of Obseva in a report on Thursday, October 31st. BidaskClub upgraded Obseva from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. HC Wainwright restated a “buy” rating and issued a $44.00 price target on shares of Obseva in a report on Wednesday, September 4th. Royal Bank of Canada restated a “buy” rating on shares of Obseva in a report on Sunday, August 11th. Finally, Zacks Investment Research upgraded Obseva from a “sell” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $24.75.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Further Reading: Capital Gains Distribution
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.